Braskem Past Earnings Performance
Past criteria checks 0/6
Braskem has been growing earnings at an average annual rate of 4%, while the Chemicals industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 12.1% per year.
Key information
4.0%
Earnings growth rate
4.0%
EPS growth rate
Chemicals Industry Growth | 12.9% |
Revenue growth rate | 12.1% |
Return on equity | -149.1% |
Net Margin | -6.5% |
Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Braskem: A Rising Odds For ADNOC Deal, Though Declining Risk-Reward (Rating Downgrade)
Apr 05Braskem: Mounting Troubles Impacting Financial Performance
Jan 25Braskem: Special Situations Trade With 100% Upside Potential
Dec 12Braskem: Glad I Sold After A 27.8% Negative RoR
Nov 09Braskem: A Speculative Bet On A Cycle Downturn
Aug 27Braskem: It's Time To Be Careful After The M&A (Rating Downgrade)
Aug 04Braskem: 22% RoR Since March, Still A 'Buy' After Q1 2023
May 24Braskem: Second Look At This International Petrochemical Player After A ~30% Drop
Dec 26Braskem S.A. GAAP EPS of $1.73 beats by $1.70, revenue of $4.83B beats by $780M
Nov 10Braskem Buoyed By A Buyout Offer
Oct 13Braskem: Time To Look Beyond The EU/North America?
Aug 03Braskem S.A.: Undervalued Moneymaker With Game-Changing Potential
May 18Braskem: Growth Stock Moving In Line With ESG Commitments
Feb 22Record Resin Prices Leaving Braskem In Great Shape
Aug 25Braskem expects to spend 9B reais to address Alagoas geological damage
Dec 31Braskem: A Justified Valuation Discount
Dec 15Mexico cuts off gas supply to Braskem plant in escalating dispute
Dec 03Braskem S.A. beats on revenue
Nov 11Revenue & Expenses BreakdownBeta
How Braskem makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 70,569 | -4,579 | 4,471 | 383 |
30 Sep 23 | 72,867 | -4,715 | 4,638 | 386 |
30 Jun 23 | 81,579 | -3,400 | 4,746 | 398 |
31 Mar 23 | 89,234 | -4,035 | 4,847 | 395 |
31 Dec 22 | 96,519 | -336 | 4,910 | 374 |
30 Sep 22 | 105,742 | 1,905 | 4,921 | 354 |
30 Jun 22 | 108,654 | 6,545 | 4,910 | 323 |
31 Mar 22 | 109,664 | 15,375 | 4,767 | 307 |
31 Dec 21 | 105,625 | 13,985 | 4,587 | 297 |
30 Sep 21 | 96,151 | 14,301 | 4,331 | 276 |
30 Jun 21 | 83,844 | 9,351 | 4,074 | 265 |
31 Mar 21 | 68,611 | -548 | 3,908 | 257 |
31 Dec 20 | 58,543 | -6,692 | 3,826 | 251 |
30 Sep 20 | 52,445 | -10,460 | 3,866 | 251 |
30 Jun 20 | 49,821 | -9,935 | 3,952 | 246 |
31 Mar 20 | 51,970 | -7,375 | 4,028 | 248 |
31 Dec 19 | 52,324 | -2,798 | 4,015 | 248 |
30 Sep 19 | 54,520 | 46 | 3,886 | 235 |
30 Jun 19 | 57,500 | 2,278 | 3,888 | 244 |
31 Mar 19 | 57,949 | 2,741 | 3,614 | 235 |
31 Dec 18 | 58,000 | 2,867 | 3,395 | 219 |
30 Sep 18 | 55,792 | 3,114 | 3,191 | 210 |
30 Jun 18 | 51,605 | 2,569 | 2,924 | 181 |
31 Mar 18 | 49,690 | 3,329 | 2,913 | 173 |
31 Dec 17 | 49,261 | 3,857 | 2,894 | 167 |
30 Sep 17 | 48,678 | 1,153 | 2,835 | 153 |
30 Jun 17 | 48,498 | 1,238 | 2,781 | 152 |
31 Mar 17 | 48,349 | 548 | 2,754 | 153 |
31 Dec 16 | 47,664 | -438 | 2,689 | 162 |
30 Sep 16 | 47,547 | 2,188 | 2,563 | 170 |
30 Jun 16 | 48,729 | 2,870 | 2,480 | 170 |
31 Mar 16 | 48,599 | 3,556 | 2,397 | 172 |
31 Dec 15 | 46,880 | 2,995 | 2,173 | 170 |
30 Sep 15 | 46,562 | 2,965 | 2,384 | 157 |
30 Jun 15 | 45,123 | 1,667 | 2,369 | 154 |
31 Mar 15 | 44,384 | 710 | 2,380 | 144 |
31 Dec 14 | 46,031 | 864 | 2,366 | 138 |
30 Sep 14 | 45,203 | 812 | 2,259 | 138 |
30 Jun 14 | 44,417 | 942 | 2,196 | 132 |
31 Mar 14 | 43,311 | 699 | 2,118 | 125 |
31 Dec 13 | 40,969 | 510 | 2,079 | 116 |
30 Sep 13 | 40,065 | 467 | 2,163 | 106 |
30 Jun 13 | 38,381 | -14 | 2,113 | 106 |
Quality Earnings: BAK is currently unprofitable.
Growing Profit Margin: BAK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BAK is unprofitable, but has reduced losses over the past 5 years at a rate of 4% per year.
Accelerating Growth: Unable to compare BAK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BAK is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-11.9%).
Return on Equity
High ROE: BAK has a negative Return on Equity (-149.13%), as it is currently unprofitable.